How to Buy Tscan Therapeutics Stock
Tscan Therapeutics Inc
TScan Therapeutics, Inc. , a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer.
Tscan Therapeutics stock last closed at $1.57, up 2.61% from the previous day, and has decreased 77.95% in one year. It has underperformed other stocks in the Biotechnology industry by 0.01 percentage points. Tscan Therapeutics stock is currently +53.92% from its 52-week low of $1.02, and -83.8% from its 52-week high of $9.69.
At the moment, there are 56.59M TCRX shares outstanding. The market value of TCRX is $88.85M. In the last 24 hours, 1.14M TCRX shares were traded.
How to Buy Tscan Therapeutics Stock
Wondering how to invest in Tscan Therapeutics stock? Here's how.
- Figure out where to buy Tscan Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of online brokerages and apps to help you decide where to buy Tscan Therapeutics stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit money your investment account: Select your payment method and add your info.
- Research Tscan Therapeutics stock: The Tscan Therapeutics ticker symbol is TCRX. Is Tscan Therapeutics stock a good investment? Should you buy shares of TCRX? How do TCRX's underlying business fundamentals look? Do top analysts think Tscan Therapeutics is a good buy? Why has TCRX's stock price moved recently? (Hint: Our stock analysis website can help you understand if TCRX is a good stock to buy).
- Place your TCRX purchase: Decide if you will purchase TCRX shares at the current market price or use a limit order to purchase TCRX stock at a particular price.
- Get the latest scoop on your investment in TCRX: Create a watchlist to watch your position in Tscan Therapeutics shares.
Step 1: Figure out where to buy Tscan Therapeutics stock
You need a brokerage account to access the NASDAQ market and buy TCRX stock.
Our recommended brokerage: eToro
Based on our research, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Technology to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal info so you are able to buy TCRX today.
How to Set Up a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create your new trading account.
- Send your data by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've finished signing up on the best stock trading app, your next step is to transfer the money for your investment:
Check out this video walkthrough for more details depositing money into your new investment account.
Step 4: Research Tscan Therapeutics stock
Once you have chosen the best place to buy Tscan Therapeutics stock, it's crucial to analyze their stock prior to investing, so you actually wrap your head around the risk and upside.
Overview of key TCRX info
Tscan Therapeutics Due Diligence Checks
WallStreetZen was created to help part-time investors perform more accurate fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on TCRX's stock page.
Is TCRX stock undervalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge TCRX's intrinsic value.
Using relative valuations methods:
- TCRX could be undervalued based on its P/B ratio of 0.37x, relative to Biotechnology industry P/B ratio of 4.16x
You can access more valuation analysis on TCRX's stock here.
Is TCRX a healthy company?
Passed Financial Due Diligence Checks:
- TCRX has cash burn of 114647000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the TCRX balance sheet.
- TCRX has $295.14M in cash and short term investments. This is enough to cover its annual cash burn of $114.65M.
- There are more short-term assets than long-term liabilities on the TCRX balance sheet.
- Total TCRX debt is lower than 5 years ago, relative to shareholder equity.
Failed Financial Due Diligence Checks:
- TCRX profit margin has gone down from -423.9% to -4,527.7% in the past year.
- TCRX has a relatively high debt to equity ratio of 0.54.
Do analysts think it's a good time to buy Tscan Therapeutics stock
Out of 4 Equities analysts who track TCRX, the consensus analyst rating on TCRX is a Strong Buy
Please note that analyst forecasts are not recommendations, nor are they financial advice.
You can dive deeper into what analysts are saying on the Tscan Therapeutics stock forecast page.
TCRX Technical Indicators
TCRX Growth Metrics
Last year, TCRX revenue was $2.82M. Over the last four year, TCRX's revenue has grown by 26.93% per year. This was slower than the Biotechnology industry average of 44.4%.
Dive into TCRX's earnings and revenue performance here.
Who is buying/selling TCRX?
In the last 12 months, executives and large shareholders at TCRX have bought more shares than they have sold.
Lynx1 Capital Management LP, 10% Owner of TCRX, was the latest TCRX insider to buy. They bought $290,100.00 worth of TCRX shares on Dec 13, 2024.
Get more info about who owns TCRX stock here.
Can I rely on TCRX as an income stream?
No, Tscan Therapeutics doesn't provide an income stream by paying out dividends.
TCRX Social Trading Data
One of the major reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Place your TCRX purchase
You have two main types of orders:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at a given price limit, use a limit order.
Click the Open button and your broker will place your order.
If you want more help buying stocks on eToro, watch the how to video below:
Step 6: Get the latest scoop on your investment in TCRX
Now that you own some shares in TCRX, you'll want to stay up-to-date on your investment.
Make a watchlist to monitor your TCRX stock.
TCRX Feed
How to Buy Stock in Tscan Therapeutics
To summarize, here are the 6 steps you need to take to buy Tscan Therapeutics stock right now:
- Figure out where to buy Tscan Therapeutics stock
- Sign up for your brokerage account
- Deposit money your investment account
- Research Tscan Therapeutics stock
- Place your TCRX purchase
- Get the latest scoop on your investment in TCRX
If you require a online brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Tscan Therapeutics, get started below.
Other Stock Buying Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.